Stay updated with breaking news from Final Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Two global Phase 3 trials in adult CLL patients demonstrated superior efficacy for BRUKINSA (zanubrutinib) in first-line and relapsed/refractory treatment settings BRUKINSA is the only BTKi to demonstrate
Fort Myers, Florida, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) that is...
/PRNewswire/ --Research findings being presented during the 64th American Society of Hematology (ASH) Annual Meeting and Exposition challenge standard...
Who else but hosts Wendy Stuart and Tym Moss could “spill the tea” on their weekly show “If These Walls Could Talk” live from Pangea
/PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American...